Want to take quizzes and track your credits?
Vaccine-induced adenopathy after COVID-19 vaccination in breast imaging has received significant media attention, with evolving literary correspondence on management. Patients’ self-report of axillary swelling following COVID-19 vaccination was reported as high as 16%.1 The National Comprehensive Cancer Network and Society of Breast Imaging recommended to consider scheduling screening breast imaging 4 to 6 weeks after the second COVID-19 vaccination dose when possible.2 However, the actual incidence, timing, and characteristics of mammographic axillary adenopathy following COVID-19 vaccination remain uncertain.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 25, 2021.
Published Online: July 22, 2021. doi:10.1001/jamaoncol.2021.3127
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Robinson KA et al. JAMA Oncology.
Corresponding Author: Saranya Chumsri, MD, Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (email@example.com).
Author Contributions: Dr Chumsri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Robinson, Maimone, Advani, Chumsri.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Robinson, Maimone, Advani, Chumsri.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Maimone, Li, Advani, Chumsri.
Obtained funding: Chumsri.
Administrative, technical, or material support: Chumsri.
Supervision: Maimone, Chumsri.
Conflict of Interest Disclosures: Dr Advani reported grants from Genentech during the conduct of the study. Dr Chumsri reported grants from Pfizer during the conduct of the study; grants from Merck & Co, the Department of Defense, and the Breast Cancer Research Foundaiton; and personal fees from Novartis, Immunomedics, Puma Biotechnology, BioTheranostics, AstraZeneca, Eisai, Athenex, and Daiichi Sankyo outside the submitted work. No other disclosures were reported.
Funding/Support: Research reported in this publication was supported by Mayo Clinic.
Role of the Funder/Sponsor: The Mayo Clinic had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
You currently have no searches saved.
You currently have no courses saved.